Aarti Drugs Limited (AARTIDRUGS.BO)
INR 330.65
(2.85%)
INR 330.65
(2.85%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 7.14 Billion INR | 3.21% |
| 2022 | 2.56 Billion INR | -10.96% |
| 2021 | 2.88 Billion INR | -25.7% |
| 2020 | 3.88 Billion INR | 81.86% |
| 2019 | 2.13 Billion INR | 28.52% |
| 2018 | 1.66 Billion INR | 0.34% |
| 2017 | 1.65 Billion INR | 41.82% |
| 2016 | 1.16 Billion INR | 20.25% |
| 2015 | 970.39 Million INR | -3.78% |
| 2014 | 1 Billion INR | 16.38% |
| 2013 | 866.6 Million INR | 31.55% |
| 2012 | 658.78 Million INR | 102.44% |
| 2011 | 325.41 Million INR | -36.09% |
| 2010 | 509.18 Million INR | -23.38% |
| 2009 | 664.56 Million INR | 26.07% |
| 2008 | 527.11 Million INR | 52.43% |
| 2007 | 345.81 Million INR | 11.74% |
| 2006 | 309.48 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 533.2 Million INR | 3.39% |
| 2024 Q1 | 515.7 Million INR | -28.6% |
| 2023 Q4 | 722.3 Million INR | 22.11% |
| 2023 Q2 | 645.2 Million INR | -10.48% |
| 2023 FY | 2.65 Billion INR | 3.21% |
| 2023 Q1 | 720.7 Million INR | -12.01% |
| 2023 Q3 | 591.5 Million INR | -8.32% |
| 2022 FY | 2.56 Billion INR | -10.96% |
| 2022 Q4 | 819.1 Million INR | 38.74% |
| 2022 Q2 | 616.6 Million INR | 12.4% |
| 2022 Q1 | 548.6 Million INR | -25.97% |
| 2022 Q3 | 590.4 Million INR | -4.25% |
| 2021 FY | 2.88 Billion INR | -25.7% |
| 2021 Q4 | 741.07 Million INR | -11.84% |
| 2021 Q3 | 840.6 Million INR | 37.06% |
| 2021 Q1 | 672.8 Million INR | -11.96% |
| 2021 Q2 | 613.3 Million INR | -8.84% |
| 2020 Q4 | 764.16 Million INR | -17.93% |
| 2020 Q1 | 1.21 Billion INR | 76.87% |
| 2020 Q2 | 1.03 Billion INR | -14.57% |
| 2020 Q3 | 931.1 Million INR | -10.37% |
| 2020 FY | 3.88 Billion INR | 81.86% |
| 2019 Q3 | 551.3 Million INR | -1.92% |
| 2019 Q4 | 687.47 Million INR | 24.7% |
| 2019 FY | 2.13 Billion INR | 28.52% |
| 2019 Q2 | 562.1 Million INR | 31.0% |
| 2019 Q1 | 429.1 Million INR | -16.23% |
| 2018 FY | 1.66 Billion INR | 0.34% |
| 2018 Q3 | 411.3 Million INR | 13.09% |
| 2018 Q1 | 422.1 Million INR | -9.01% |
| 2018 Q4 | 512.21 Million INR | 24.54% |
| 2018 Q2 | 363.7 Million INR | -13.84% |
| 2017 FY | 1.65 Billion INR | 41.82% |
| 2017 Q4 | 463.9 Million INR | 32.47% |
| 2017 Q3 | 350.2 Million INR | 1.39% |
| 2017 Q2 | 345.4 Million INR | 106.58% |
| 2017 Q1 | 167.2 Million INR | -94.91% |
| 2016 Q1 | 285.5 Million INR | -91.57% |
| 2016 Q4 | 3.28 Billion INR | 1263.47% |
| 2016 FY | 1.16 Billion INR | 20.25% |
| 2016 Q2 | 326.2 Million INR | 14.26% |
| 2016 Q3 | 240.9 Million INR | -26.15% |
| 2015 Q2 | 227.2 Million INR | -7.45% |
| 2015 Q4 | 3.38 Billion INR | 1387.53% |
| 2015 Q3 | 227.8 Million INR | 0.26% |
| 2015 Q1 | 245.5 Million INR | -5.04% |
| 2015 FY | 970.39 Million INR | -3.78% |
| 2014 Q2 | 255.1 Million INR | 12.78% |
| 2014 Q4 | 258.54 Million INR | -3.71% |
| 2014 FY | 1 Billion INR | 16.38% |
| 2014 Q3 | 268.5 Million INR | 5.25% |
| 2014 Q1 | 226.2 Million INR | -18.81% |
| 2013 Q2 | 204.6 Million INR | 20.14% |
| 2013 Q3 | 212.2 Million INR | 3.71% |
| 2013 Q4 | 278.6 Million INR | 31.29% |
| 2013 FY | 866.6 Million INR | 31.55% |
| 2013 Q1 | 170.3 Million INR | 126.99% |
| 2012 FY | 658.78 Million INR | 102.44% |
| 2012 Q1 | 475.4 Million INR | 0.0% |
| 2012 Q2 | 550.8 Million INR | 15.86% |
| 2012 Q3 | 548.1 Million INR | -0.49% |
| 2012 Q4 | -630.98 Million INR | -215.12% |
| 2011 FY | 325.41 Million INR | -36.09% |
| 2010 FY | 509.18 Million INR | -23.38% |
| 2009 FY | 664.56 Million INR | 26.07% |
| 2008 FY | 527.11 Million INR | 52.43% |
| 2007 FY | 345.81 Million INR | 11.74% |
| 2006 FY | 309.48 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | -24.151% |
| Aurobindo Pharma Limited | 42.2 Billion INR | 83.061% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 20.386% |
| Granules India Limited | 6.81 Billion INR | -4.871% |
| Indoco Remedies Limited | 1.29 Billion INR | -453.072% |
| Achyut Healthcare Limited | 4.43 Million INR | -160979.811% |
| Ajanta Pharma Limited | 19.67 Billion INR | 63.67% |
| Alkem Laboratories Limited | 19.46 Billion INR | 63.268% |
| Alpa Laboratories Limited | 184.49 Million INR | -3774.709% |
| Brooks Laboratories Limited | 14.44 Million INR | -49406.385% |
| AstraZeneca Pharma India Limited | 1.71 Billion INR | -316.228% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | -480.724% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 89.445% |
| Eris Lifesciences Limited | 5.18 Billion INR | -37.96% |
| FDC Limited | 2.98 Billion INR | -139.391% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | -9.94% |
| Gufic Biosciences Limited | 1.32 Billion INR | -437.534% |
| Ind-Swift Laboratories Limited | 4.42 Billion INR | -61.716% |
| Ipca Laboratories Limited | 7.98 Billion INR | 10.424% |
| Jagsonpal Pharmaceuticals Limited | 508.13 Million INR | -1306.869% |
| Krebs Biochemicals & Industries Limited | -151.95 Million INR | 4804.437% |
| Lasa Supergenerics Limited | -458 Million INR | 1660.839% |
| Laurus Labs Limited | 3.94 Billion INR | -81.044% |
| Lupin Limited | 28.04 Billion INR | 74.509% |
| Mankind Pharma Limited | 21.51 Billion INR | 66.778% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Medico Remedies Limited | 100.3 Million INR | -7027.34% |
| Megasoft Limited | -121.1 Million INR | 6002.961% |
| NATCO Pharma Limited | 25.96 Billion INR | 72.465% |
| Piramal Pharma Limited | 4.55 Billion INR | -56.877% |
| RPG Life Sciences Limited | 2.29 Billion INR | -211.858% |
| Sigachi Industries Limited | 1.47 Billion INR | -385.022% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 93.146% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | -55.149% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -2768.082% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Wanbury Limited | 569.71 Million INR | -1154.787% |
| Windlas Biotech Limited | 1.29 Billion INR | -450.372% |
| ZIM Laboratories Limited | 253.82 Million INR | -2716.354% |
| Zydus Lifesciences Limited | 43.1 Billion INR | 83.416% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 273.722% |
| Divi's Laboratories Limited | 33.08 Billion INR | 78.39% |
| Hester Biosciences Limited | 364.81 Million INR | -1859.574% |
| Procter & Gamble Health Limited | 2.78 Billion INR | -156.594% |
| Amrutanjan Health Care Limited | 457.54 Million INR | -1462.412% |
| Bal Pharma Limited | 233.9 Million INR | -2956.198% |
| Strides Pharma Science Limited | 5.22 Billion INR | -36.796% |
| Venus Remedies Limited | 534.65 Million INR | -1237.082% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | -128.531% |
| Nectar Lifesciences Limited | 923.8 Million INR | -673.834% |
| Shilpa Medicare Limited | 1.36 Billion INR | -423.228% |
| IOL Chemicals and Pharmaceuticals Limited | 1.59 Billion INR | -347.691% |
| Suven Life Sciences Limited | -1.22 Billion INR | 683.178% |
| Ind-Swift Limited | 1.22 Billion INR | -483.11% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.28 Billion INR | 49.949% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 285.541% |
| Themis Medicare Limited | 392.58 Million INR | -1720.918% |
| Hikal Limited | 32.11 Million INR | -22163.226% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 71.783% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Novartis India Limited | 626.5 Million INR | -1041.057% |
| Wockhardt Limited | -670 Million INR | 1166.973% |
| Jubilant Pharmova Limited | 5.18 Billion INR | -37.767% |
| Biofil Chemicals and Pharmaceuticals Limited | 9.06 Million INR | -78728.52% |
| Neuland Laboratories Limited | 5.31 Billion INR | -34.423% |
| Morepen Laboratories Limited | 4.17 Billion INR | -71.275% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -3336.06% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -25935.115% |